TrialJournal for immunotherapy of cancer2020

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Romain Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.